Other formats:
BibTeX
LaTeX
RIS
@article{1809821,
author = {Singh, A. and Hussain, Mohammad Salman and Jha, R. and Jayraj, A. S. and Klugar, Miloslav and Antony, B.},
article_location = {HOBOKEN},
article_number = {4},
doi = {http://dx.doi.org/10.1111/jebm.12456},
keywords = {hepatocellular carcinoma; meta-analysis; pharmacoepidemiological study; proton pump inhibitors; real-world evidence; systematic review},
language = {eng},
issn = {1756-5383},
journal = {JOURNAL OF EVIDENCE BASED MEDICINE},
title = {Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data},
url = {https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456},
volume = {14},
year = {2021}
}
TY - JOUR
ID - 1809821
AU - Singh, A. - Hussain, Mohammad Salman - Jha, R. - Jayraj, A. S. - Klugar, Miloslav - Antony, B.
PY - 2021
TI - Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data
JF - JOURNAL OF EVIDENCE BASED MEDICINE
VL - 14
IS - 4
SP - 278-280
EP - 278-280
PB - WILEY
SN - 17565383
KW - hepatocellular carcinoma
KW - meta-analysis
KW - pharmacoepidemiological study
KW - proton pump inhibitors
KW - real-world evidence
KW - systematic review
UR - https://onlinelibrary.wiley.com/doi/epdf/10.1111/jebm.12456
N2 - Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.
ER -
SINGH, A., Mohammad Salman HUSSAIN, R. JHA, A. S. JAYRAJ, Miloslav KLUGAR and B. ANTONY. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. \textit{JOURNAL OF EVIDENCE BASED MEDICINE}. HOBOKEN: WILEY, 2021, vol.~14, No~4, p.~278-280. ISSN~1756-5383. Available from: https://dx.doi.org/10.1111/jebm.12456.
|
